##common.pageHeaderLogo.altText##

Review article: Medical guidelines

Vol. 155 No. 7 (2025)

The updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma

Cite this as:
Swiss Med Wkly. 2025;155:4210
Published
08.07.2025

Summary

Despite the globally rising incidence of melanoma, mortality rates have decreased by approximately 18% in Caucasian populations following the introduction of effective systemic treatments.

Thanks to new molecular insights, the management of cutaneous melanoma has undergone several transformations over the past decade. The existing guidelines were last updated in 2016 to provide evidence-based practical recommendations for melanoma specialists across Switzerland. Recent data on surgical, radiotherapeutic and mainly systemic treatment with the implementation of adjuvant and neoadjuvant treatments in the current melanoma management have made modifications of the treatment and follow-up recommendations necessary.

References

  1. Forsea AM, Del Marmol V, de Vries E, Bailey EE, Geller AC. Melanoma incidence and mortality in Europe: new estimates, persistent disparities. Br J Dermatol. 2012 Nov;167(5):1124–30. 10.1111/j.1365-2133.2012.11125.x
  2. Dummer R, Siano M, Hunger RE, Lindenblatt N, Braun R, Michielin O, et al. The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma. Swiss Med Wkly. 2016 Feb;146:w14279. 10.4414/smw.2016.14279
  3. Oxman AD, Sackett DL, Guyatt GH; The Evidence-Based Medicine Working Group. Users’ guides to the medical literature. I. How to get started. JAMA. 1993 Nov;270(17):2093–5. doi: https://doi.org/10.1001/jama.1993.03510170083036
  4. McGovern VJ. The classification of melanoma and its relationship with prognosis. Pathology. 1970 Apr;2(2):85–98. 10.3109/00313027009077330
  5. Clark WH Jr, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969 Mar;29(3):705–27.
  6. WHO blue book: classification of skin tumours 5th edition.
  7. Krauthammer M, Kong Y, Bacchiocchi A, Evans P, Pornputtapong N, Wu C, et al. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat Genet. 2015 Sep;47(9):996–1002. 10.1038/ng.3361
  8. Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, Kageshita T, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst. 2003 Dec;95(24):1878–90. 10.1093/jnci/djg123
  9. Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, et al. Whole-genome landscapes of major melanoma subtypes. Nature. 2017 May;545(7653):175–80. 10.1038/nature22071
  10. Mihic-Probst D, Perren A, Schmid S, Saremaslani P, Komminoth P, Heitz PU. Absence of BRAF gene mutations differentiates spitz nevi from malignant melanoma. Anticancer Res. 2004;24(4):2415–8.
  11. Barnhill RL, Elder DE, Piepkorn MW, Knezevich SR, Reisch LM, Eguchi MM, et al. Revision of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis Classification Schema for Melanocytic Lesions: A Consensus Statement. JAMA Netw Open. 2023 Jan;6(1):e2250613. 10.1001/jamanetworkopen.2022.50613
  12. Grob JJ, Bonerandi JJ. The ‘ugly duckling’ sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening. Arch Dermatol. 1998 Jan;134(1):103–4. 10.1001/archderm.134.1.103-a
  13. Salerni G, Carrera C, Lovatto L, Martí-Laborda RM, Isern G, Palou J, et al. Characterization of 1152 lesions excised over 10 years using total-body photography and digital dermatoscopy in the surveillance of patients at high risk for melanoma. J Am Acad Dermatol. 2012 Nov;67(5):836–45. 10.1016/j.jaad.2012.01.028
  14. Zhang S, Wang Y, Zheng Q, Li J, Huang J, Long X. Artificial intelligence in melanoma: A systematic review. J Cosmet Dermatol. 2022 Nov;21(11):5993–6004. 10.1111/jocd.15323
  15. Phillips M, Marsden H, Jaffe W, Matin RN, Wali GN, Greenhalgh J, et al. Assessment of Accuracy of an Artificial Intelligence Algorithm to Detect Melanoma in Images of Skin Lesions. JAMA Netw Open. 2019 Oct;2(10):e1913436. 10.1001/jamanetworkopen.2019.13436
  16. McLeod M, Choudhary S, Giannakakis G, Nouri K. Surgical treatments for lentigo maligna: a review. Dermatol Surg. 2011 Sep;37(9):1210–28. 10.1111/j.1524-4725.2011.02042.x
  17. Shain AH, Yeh I, Kovalyshyn I, Sriharan A, Talevich E, Gagnon A, et al. The Genetic Evolution of Melanoma from Precursor Lesions. N Engl J Med. 2015 Nov;373(20):1926–36. 10.1056/NEJMoa1502583
  18. Spaccarelli N, Drozdowski R, Peters MS, Grant-Kels JM. Dysplastic nevus part II: Dysplastic nevi: Molecular/genetic profiles and management. J Am Acad Dermatol. 2023 Jan;88(1):13–20. 10.1016/j.jaad.2022.05.071
  19. Balch CM, Morton DL, Gershenwald JE, McMasters KM, Nieweg OE, Powell B, et al. Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol. 2009 May;60(5):872–5. 10.1016/j.jaad.2008.09.067
  20. Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al.; for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017 Nov;67(6):472–92. 10.3322/caac.21409
  21. Kött J, Zimmermann N, Zell T, Rünger A, Heidrich I, Geidel G, et al. Sentinel lymph node risk prognostication in primary cutaneous melanoma through tissue-based profiling, potentially redefining the need for sentinel lymph node biopsy. Eur J Cancer. 2024 May;202:113989. 10.1016/j.ejca.2024.113989
  22. Riber-Hansen R, Sjoegren P, Hamilton-Dutoit SJ, Steiniche T. Extensive pathological analysis of selected melanoma sentinel lymph nodes: high metastasis detection rates at reduced workload. Ann Surg Oncol. 2008 May;15(5):1492–501. 10.1245/s10434-008-9847-8
  23. Cook MG, Massi D, Szumera-Ciećkiewicz A, Van den Oord J, Blokx W, van Kempen LC, et al.; EORTC Melanoma Group. An updated European Organisation for Research and Treatment of Cancer (EORTC) protocol for pathological evaluation of sentinel lymph nodes for melanoma. Eur J Cancer. 2019 Jun;114:1–7. 10.1016/j.ejca.2019.03.010
  24. Riber-Hansen R, Hamilton-Dutoit SJ, Steiniche T. Nodal distribution, stage migration due to diameter measurement and the prognostic significance of metastasis volume in melanoma sentinel lymph nodes: a validation study. APMIS. 2014 Oct;122(10):968–75. 10.1111/apm.12240
  25. Laeijendecker AE, El Sharouni MA, Stathonikos N, Spoto CP, van de Wiel BA, Eijken EJ, et al. The difficulty with measuring the largest melanoma tumour diameter in sentinel lymph nodes. J Clin Pathol. 2024 May;77(6):372–7. 10.1136/jcp-2023-209354
  26. Mihic-Probst D, Saremaslani P, Komminoth P, Heitz PU. Immunostaining for the tumour suppressor gene p16 product is a useful marker to differentiate melanoma metastasis from lymph-node nevus. Virchows Arch. 2003 Dec;443(6):745–51. 10.1007/s00428-003-0897-9
  27. Broman KK, Richman J, Bhatia S. Evidence and implementation gaps in management of sentinel node-positive melanoma in the United States. Surgery. 2022 Jul;172(1):226–33. 10.1016/j.surg.2021.12.025
  28. Cochran AJ, Balda BR, Starz H, Bachter D, Krag DN, Cruse CW, et al.; The Augsburg Consensus. The Augsburg Consensus. Techniques of lymphatic mapping, sentinel lymphadenectomy, and completion lymphadenectomy in cutaneous malignancies. Cancer. 2000 Jul;89(2):236–41. doi: https://doi.org/10.1002/1097-0142(20000715)89:2<236::AID-CNCR5>3.0.CO;2-0
  29. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF, et al.; MSLT Group. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014 Feb;370(7):599–609. 10.1056/NEJMoa1310460
  30. Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, et al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med. 2017 Jun;376(23):2211–22. 10.1056/NEJMoa1613210
  31. Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer NH, Berking C, et al.; German Dermatologic Cooperative Oncology Group. Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node. J Clin Oncol. 2019 Nov;37(32):3000–8. 10.1200/JCO.18.02306
  32. Hall BJ, Schmidt RL, Sharma RR, Layfield LJ. Fine-needle aspiration cytology for the diagnosis of metastatic melanoma: systematic review and meta-analysis. Am J Clin Pathol. 2013 Nov;140(5):635–42. 10.1309/AJCPWSDDHLLW40WI
  33. Morton DL, Cochran AJ, Thompson JF, Elashoff R, Essner R, Glass EC, et al.; Multicenter Selective Lymphadenectomy Trial Group. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg. 2005 Sep;242(3):302–11. 10.1097/01.sla.0000181092.50141.fa
  34. Michielin O, van Akkooi A, Lorigan P, Ascierto PA, Dummer R, Robert C, et al. ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020 Nov;31(11):1449–61. 10.1016/j.annonc.2020.07.005
  35. Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, et al. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 Feb;19(2):181–93. 10.1016/S1470-2045(18)30015-9
  36. Blank CU, Rozeman EA, Fanchi LF, Sikorska K, van de Wiel B, Kvistborg P, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 2018 Nov;24(11):1655–61. 10.1038/s41591-018-0198-0
  37. Long GV, Saw RP, Lo S, Nieweg OE, Shannon KF, Gonzalez M, et al. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. Lancet Oncol. 2019 Jul;20(7):961–71. 10.1016/S1470-2045(19)30331-6
  38. Liu J, Blake SJ, Yong MC, Harjunpää H, Ngiow SF, Takeda K, et al. Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. Cancer Discov. 2016 Dec;6(12):1382–99. 10.1158/2159-8290.CD-16-0577
  39. Menzies AM, Amaria RN, Rozeman EA, Huang AC, Tetzlaff MT, van de Wiel BA, et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med. 2021 Feb;27(2):301–9. 10.1038/s41591-020-01188-3
  40. Reijers IL, Menzies AM, van Akkooi AC, Versluis JM, van den Heuvel NM, Saw RP, et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med. 2022 Jun;28(6):1178–88. 10.1038/s41591-022-01851-x
  41. Amaria RN, et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma (vol 24, pg 1649, 2018) . Nat Med. 2018 Dec;24(12):1942–1942. 10.1038/s41591-018-0252-y
  42. Patel SP, Othus M, Moon J, Tetzlaff M, Buchbinder EI, Sondak VK, et al. S1801: A randomized trial of adjuvant versus neoadjuvant pembrolizumab for melanoma . J Clin Oncol. 2021 May;39(15):TPS9585. 10.1200/JCO.2021.39.15_suppl.TPS9585
  43. Dummer R, Gyorki DE, Hyngstrom J, Berger AC, Conry R, Demidov L, et al. Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial. Nat Med. 2021 Oct;27(10):1789–96. 10.1038/s41591-021-01510-7
  44. Blank CU, Lucas MW, Scolyer RA, van de Wiel BA, Menzies AM, Lopez-Yurda M, et al. Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma. N Engl J Med. 2024 Nov;391(18):1696–708. 10.1056/NEJMoa2402604
  45. Ascierto PA, Del Vecchio M, Robert C, Mackiewicz A, Chiarion-Sileni V, Arance A, et al. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2017 May;18(5):611–22. 10.1016/S1470-2045(17)30231-0
  46. Eggermont AM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med. 2018 May;378(19):1789–801. 10.1056/NEJMoa1802357
  47. Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med. 2017 Nov;377(19):1813–23. 10.1056/NEJMoa1708539
  48. Tarhini AA, Lee SJ, Hodi FS, Rao UN, Cohen GI, Hamid O, et al.; Phase III Study of Adjuvant Ipilimumab. Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: north American Intergroup E1609. J Clin Oncol. 2020 Feb;38(6):567–75. 10.1200/JCO.19.01381
  49. Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al.; CheckMate 238 Collaborators. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med. 2017 Nov;377(19):1824–35. 10.1056/NEJMoa1709030
  50. Weber JS, Schadendorf D, Del Vecchio M, Larkin J, Atkinson V, Schenker M, et al. Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915). J Clin Oncol. 2023 Jan;41(3):517–27. 10.1200/JCO.22.00533
  51. Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, et al.; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC). European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022. Eur J Cancer. 2022 Jul;170:256–84. 10.1016/j.ejca.2022.04.018
  52. Zimmer L, Livingstone E, Hassel JC, Fluck M, Eigentler T, Loquai C, et al.; Dermatologic Cooperative Oncology Group. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020 May;395(10236):1558–68. 10.1016/S0140-6736(20)30417-7
  53. Larkin J, Weber J, Del Vecchio M, Gogas H, Arance AM, Dalle S, et al. Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria. Eur J Cancer. 2022 Sep;173:285–96. 10.1016/j.ejca.2022.06.041
  54. Eggermont AMM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, et al. Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma. NEJM Evid. 2022 Nov;1(11):EVIDoa2200214. doi: 10.1056/EVIDoa2200214. Epub 2022 Sep 10. PMID: 38319852.
  55. Eggermont AM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, et al. Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial. Eur J Cancer. 2024 Nov;211:114327. 10.1016/j.ejca.2024.114327
  56. Dummer R, Hauschild A, Santinami M, Atkinson V, Mandalà M, Kirkwood JM, et al. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med. 2020 Sep;383(12):1139–48. 10.1056/NEJMoa2005493
  57. Long GV, Hauschild A, Santinami M, Kirkwood JM, Atkinson V, Mandala M, et al. Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med. 2024 Nov;391(18):1709–20. 10.1056/NEJMoa2404139
  58. Satzger I, Leiter U, Gräger N, Keim U, Garbe C, Gutzmer R. Melanoma-specific survival in patients with positive sentinel lymph nodes: relevance of sentinel tumor burden. Eur J Cancer. 2019 Dec;123:83–91. 10.1016/j.ejca.2019.07.004
  59. Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, et al.; KEYNOTE-716 Investigators. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022 Apr;399(10336):1718–29. 10.1016/S0140-6736(22)00562-1
  60. Kirkwood JM, Del Vecchio M, Weber J, Hoeller C, Grob JJ, Mohr P, et al. Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nat Med. 2023 Nov;29(11):2835–43. 10.1038/s41591-023-02583-2
  61. Luke JJ, Ascierto PA, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, et al. Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. J Clin Oncol. 2024 May;42(14):1619–24. 10.1200/JCO.23.02355
  62. Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024 Feb;403(10427):632–44. 10.1016/S0140-6736(23)02268-7
  63. Sosman JA, Moon J, Tuthill RJ, Warneke JA, Vetto JT, Redman BG, et al. A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer. 2011 Oct;117(20):4740–06. 10.1002/cncr.26111
  64. McLoughlin JM, Zager JS, Sondak VK, Berk LB. Treatment options for limited or symptomatic metastatic melanoma. Cancer Control. 2008 Jul;15(3):239–47. 10.1177/107327480801500307
  65. Bello DM, Panageas KS, Hollmann T, Shoushtari AN, Momtaz P, Chapman PB, et al. Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade. Ann Surg Oncol. 2020 Apr;27(4):1180–8. 10.1245/s10434-019-08099-9
  66. Farshad A, Burg G, Panizzon R, Dummer R. A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. Br J Dermatol. 2002 Jun;146(6):1042–6. 10.1046/j.1365-2133.2002.04750.x
  67. Fogarty GB, Hong A, Scolyer RA, Lin E, Haydu L, Guitera P, et al. Radiotherapy for lentigo maligna: a literature review and recommendations for treatment. Br J Dermatol. 2014 Jan;170(1):52–8. 10.1111/bjd.12611
  68. Hendrickx A, Cozzio A, Plasswilm L, Panje CM. Radiotherapy for lentigo maligna and lentigo maligna melanoma - a systematic review. Radiat Oncol. 2020 Jul;15(1):174. 10.1186/s13014-020-01615-2
  69. Hedblad MA, Mallbris L. Grenz ray treatment of lentigo maligna and early lentigo maligna melanoma. J Am Acad Dermatol. 2012 Jul;67(1):60–8. 10.1016/j.jaad.2011.06.029
  70. Schmid-Wendtner MH, Brunner B, Konz B, Kaudewitz P, Wendtner CM, Peter RU, et al. Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients. J Am Acad Dermatol. 2000 Sep;43(3):477–82. 10.1067/mjd.2000.106241
  71. S. N. L. Angela M Hong, Gerald B Fogarty, Jonathan Stretch, Wei Wang, Pablo Fernandez Penas, Richard CW Martin, Matthew C Foote, Hans Peter Soyer, Jeremy Ruben, Victoria Mar, Lilian Rocha, Christopher Wratten, Helena Collgros, Amanda Regio Pereira, Bruna Melhoranse Gouveia, Richard A Scolyer, Madeleine T King, Pascale Guitera, A randomised, controlled, multicentre trial of imiquimod versus radiotherapy for lentigo maligna., Journal of Clinical Oncology, vol. 42, Number 16_suppl, 2024.
  72. Overgaard J, von der Maase H, Overgaard M. A randomized study comparing two high-dose per fraction radiation schedules in recurrent or metastatic malignant melanoma. Int J Radiat Oncol Biol Phys. 1985 Oct;11(10):1837–9. 10.1016/0360-3016(85)90042-2
  73. Sause WT, Cooper JS, Rush S, Ago CT, Cosmatos D, Coughlin CT, et al. Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys. 1991 Mar;20(3):429–32. 10.1016/0360-3016(91)90053-7
  74. Hughes TM, Williams GJ, Gyorki DE, Kelly JW, Stretch JR, Varey AH, et al. Desmoplastic melanoma: a review of its pathology and clinical behaviour, and of management recommendations in published guidelines. J Eur Acad Dermatol Venereol. 2021 Jun;35(6):1290–8. 10.1111/jdv.17154
  75. Rule WG, Allred JB, Pockaj BA, Markovic SN, DiCaudo DJ, Erickson LA, et al. Results of NCCTG N0275 (Alliance) - a phase II trial evaluating resection followed by adjuvant radiation therapy for patients with desmoplastic melanoma. Cancer Med. 2016 Aug;5(8):1890–6. 10.1002/cam4.783
  76. Strom T, Caudell JJ, Han D, Zager JS, Yu D, Cruse CW, et al. Radiotherapy influences local control in patients with desmoplastic melanoma. Cancer. 2014 May;120(9):1369–78. 10.1002/cncr.28412
  77. Guadagnolo BA, Prieto V, Weber R, Ross MI, Zagars GK. The role of adjuvant radiotherapy in the local management of desmoplastic melanoma. Cancer. 2014 May;120(9):1361–8. 10.1002/cncr.28415
  78. Oliver DE, Patel KR, Parker D, Delman KA, Lawson DH, Kudchadkar RR, et al. The emerging role of radiotherapy for desmoplastic melanoma and implications for future research. Melanoma Res. 2015 Apr;25(2):95–102. 10.1097/CMR.0000000000000139
  79. Vongtama R, Safa A, Gallardo D, Calcaterra T, Juillard G. Efficacy of radiation therapy in the local control of desmoplastic malignant melanoma. Head Neck. 2003 Jun;25(6):423–8. 10.1002/hed.10263
  80. Burmeister BH, Henderson MA, Ainslie J, Fisher R, Di Iulio J, Smithers BM, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial . Lancet Oncol. 2012 Jun;13(6):589–97. 10.1016/S1470-2045(12)70138-9
  81. Agrawal S, Kane JM 3rd, Guadagnolo BA, Kraybill WG, Ballo MT. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer. 2009 Dec;115(24):5836–44. 10.1002/cncr.24627
  82. Fallon M, Giusti R, Aielli F, Hoskin P, Rolke R, Sharma M, et al.; ESMO Guidelines Committee. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018 Oct;29 Suppl 4:iv166–91. 10.1093/annonc/mdy152
  83. Lutz S, Balboni T, Jones J, Lo S, Petit J, Rich SE, et al. Palliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol. 2017;7(1):4–12. 10.1016/j.prro.2016.08.001
  84. Harada H, Katagiri H, Kamata M, Yoshioka Y, Asakura H, Hashimoto T, et al. Radiological response and clinical outcome in patients with femoral bone metastases after radiotherapy. J Radiat Res. 2010;51(2):131–6. 10.1269/jrr.09096
  85. Sprave T, Hees K, Bruckner T, Foerster R, Bostel T, Schlampp I, et al. The influence of fractionated radiotherapy on the stability of spinal bone metastases: a retrospective analysis from 1047 cases. Radiat Oncol. 2018 Jul;13(1):134. 10.1186/s13014-018-1082-2
  86. Sprave T, Verma V, Förster R, Schlampp I, Hees K, Bruckner T, et al. Bone density and pain response following intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for vertebral metastases - secondary results of a randomized trial. Radiat Oncol. 2018 Oct;13(1):212. 10.1186/s13014-018-1161-4
  87. Gillespie EF, Yang JC, Mathis NJ, Marine CB, White C, Zhang Z, et al. Prophylactic Radiation Therapy Versus Standard of Care for Patients With High-Risk Asymptomatic Bone Metastases: A Multicenter, Randomized Phase II Clinical Trial. J Clin Oncol. 2024 Jan;42(1):38–46. 10.1200/JCO.23.00753
  88. Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019 May;393(10185):2051–8. 10.1016/S0140-6736(18)32487-5
  89. Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. J Clin Oncol. 2020 Sep;38(25):2830–8. 10.1200/JCO.20.00818
  90. Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020 Jan;21(1):e18–28. 10.1016/S1470-2045(19)30718-1
  91. Kroeze SG, Fritz C, Hoyer M, Lo SS, Ricardi U, Sahgal A, et al. Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review. Cancer Treat Rev. 2017 Feb;53:25–37. 10.1016/j.ctrv.2016.11.013
  92. Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, et al.; CheckMate 067 Investigators. Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma. N Engl J Med. 2025 Jan;392(1):11–22. 10.1056/NEJMoa2407417
  93. Long GV, Carlino MS, McNeil C, Ribas A, Gaudy-Marqueste C, Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study. Ann Oncol. 2024 Dec;35(12):1191–9. 10.1016/j.annonc.2024.08.2330
  94. Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, et al.; RELATIVITY-047 Investigators. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022 Jan;386(1):24–34. 10.1056/NEJMoa2109970
  95. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al.; KEYNOTE-006 investigators. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015 Jun;372(26):2521–32. 10.1056/NEJMoa1503093
  96. Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, et al. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. J Clin Oncol. 2017 Mar;35(7):785–92. 10.1200/JCO.2015.66.1389
  97. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2017 Oct;377(14):1345–56. 10.1056/NEJMoa1709684
  98. Lebbé C, Meyer N, Mortier L, Marquez-Rodas I, Robert C, Rutkowski P, et al. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. J Clin Oncol. 2019 Apr;37(11):867–75. 10.1200/JCO.18.01998
  99. Ellebaek E, Khan S, Bastholt L, Schmidt H, Haslund CA, Donia M, et al. PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma. Eur J Cancer. 2024 Feb;198:113476. 10.1016/j.ejca.2023.113476
  100. Pires da Silva I, Ahmed T, McQuade JL, Nebhan CA, Park JJ, Versluis JM, et al. Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. J Clin Oncol. 2022 Apr;40(10):1068–80. 10.1200/JCO.21.01701
  101. Pires da Silva I, Ahmed T, Reijers IL, Weppler AM, Betof Warner A, Patrinely JR, et al. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. Lancet Oncol. 2021 Jun;22(6):836–47. 10.1016/S1470-2045(21)00097-8
  102. Pires da Silva I, Zakria D, Ahmed T, Trojanello C, Dimitriou F, Allayous C, et al. Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma. J Immunother Cancer. 2022 Jul;10(7):e004610. 10.1136/jitc-2022-004610
  103. Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016 Sep;17(9):1248–60. 10.1016/S1470-2045(16)30122-X
  104. Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018 May;19(5):603–15. 10.1016/S1470-2045(18)30142-6
  105. Atkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong TG, et al. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023 Jan;41(2):186–97. 10.1200/JCO.22.01763
  106. Ascierto PA, Mandalà M, Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V, et al. Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial. J Clin Oncol. 2023 Jan;41(2):212–21. 10.1200/JCO.21.02961
  107. Dixon-Douglas JR, Patel RP, Somasundram PM, McArthur GA. Triplet Therapy in Melanoma - Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies. Curr Oncol Rep. 2022 Aug;24(8):1071–9. 10.1007/s11912-022-01243-x
  108. Ascierto PA, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, et al. Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study. Lancet Oncol. 2023 Jan;24(1):33–44. 10.1016/S1470-2045(22)00687-8
  109. Schadendorf D, Dummer R, Robert C, Ribas A, Sullivan RJ, Panella T, et al. STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma. Future Oncol. 2022 Jun;18(17):2041–51. 10.2217/fon-2021-1486
  110. Ribas A, Chesney J, Long GV, Kirkwood JM, Dummer R, Puzanov I, et al. ∙∙1037O MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL). Ann Oncol. 2021;32 suppl. 5:S868–9. doi: https://doi.org/10.1016/j.annonc.2021.08.1422
  111. Ascierto PA, Long GV, Robert C, Brady B, Dutriaux C, Di Giacomo AM, et al. Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. JAMA Oncol. 2019 Feb;5(2):187–94. 10.1001/jamaoncol.2018.4514
  112. Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer. 2004 Aug;40(12):1825–36. doi: https://doi.org/10.1016/j.ejca.2004.04.030
  113. Patel PM, Suciu S, Mortier L, Kruit WH, Robert C, Schadendorf D, et al.; EORTC Melanoma Group. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer. 2011 Jul;47(10):1476–83. 10.1016/j.ejca.2011.04.030
  114. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000 Jan;18(1):158–66. 10.1200/JCO.2000.18.1.158
  115. von Moos R, Seifert B, Simcock M, Goldinger SM, Gillessen S, Ochsenbein A, et al.; Swiss Group for Clinical Cancer Research (SAKK). First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Ann Oncol. 2012 Feb;23(2):531–6. 10.1093/annonc/mdr126
  116. Birck A, Kirkin AF, Zeuthen J, Hou-Jensen K. Expression of basic fibroblast growth factor and vascular endothelial growth factor in primary and metastatic melanoma from the same patients. Melanoma Res. 1999 Aug;9(4):375–81. 10.1097/00008390-199908000-00006
  117. Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL; Tumour Angiogenesis Research Group. Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway—a report of the Tumour Angiogenesis Research Group. J Clin Oncol. 2006 Sep;24(26):4301–8. 10.1200/JCO.2006.05.9501
  118. Petrelli F, Ardito R, Merelli B, Lonati V, Cabiddu M, Seghezzi S, et al. Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and meta-analysis. Melanoma Res. 2019 Feb;29(1):1–12. 10.1097/CMR.0000000000000520
  119. Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, et al. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol. 2012 Jan;30(1):34–41. 10.1200/JCO.2011.34.6270
  120. Arance A, de la Cruz-Merino L, Petrella TM, Jamal R, Ny L, Carneiro A, et al. Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination. J Clin Oncol. 2023 Jan;41(1):75–85. 10.1200/JCO.22.00221
  121. Sarnaik AA, Hamid O, Khushalani NI, Lewis KD, Medina T, Kluger HM, et al. Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. J Clin Oncol. 2021 Aug;39(24):2656–66. 10.1200/JCO.21.00612
  122. Bernard ME, Wegner RE, Reineman K, Heron DE, Kirkwood J, Burton SA, et al. Linear accelerator based stereotactic radiosurgery for melanoma brain metastases . J Cancer Res Ther. 2012;8(2):215–21. 10.4103/0973-1482.98973
  123. Nieder C, Grosu AL, Gaspar LE. Stereotactic radiosurgery (SRS) for brain metastases: a systematic review. Radiat Oncol. 2014 Jul;9(1):155. 10.1186/1748-717X-9-155
  124. Bates JE, Youn P, Usuki KY, Walter KA, Huggins CF, Okunieff P, et al. Brain metastasis from melanoma: the prognostic value of varying sites of extracranial disease. J Neurooncol. 2015 Nov;125(2):411–8. 10.1007/s11060-015-1932-9
  125. Rades D, Sehmisch L, Huttenlocher S, Blank O, Hornung D, Terheyden P, et al. Radiosurgery alone for 1-3 newly-diagnosed brain metastases from melanoma: impact of dose on treatment outcomes. Anticancer Res. 2014 Sep;34(9):5079–82.
  126. Christ SM, Mahadevan A, Floyd SR, Lam FC, Chen CC, Wong ET, et al. Stereotactic radiosurgery for brain metastases from malignant melanoma. Surg Neurol Int. 2015 Aug;6(13 Suppl 12):S355–65. 10.4103/2152-7806.163315
  127. DiLuna ML, King JT Jr, Knisely JP, Chiang VL. Prognostic factors for survival after stereotactic radiosurgery vary with the number of cerebral metastases . Cancer. 2007 Jan;109(1):135–45. 10.1002/cncr.22367
  128. Liew DN, Kano H, Kondziolka D, Mathieu D, Niranjan A, Flickinger JC, et al. Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article . J Neurosurg. 2011 Mar;114(3):769–79. 10.3171/2010.5.Jns1014 doi: https://doi.org/10.3171/2010.5.JNS1014
  129. Mathieu D, Kondziolka D, Cooper PB, Flickinger JC, Niranjan A, Agarwala S, et al. Gamma knife radiosurgery in the management of malignant melanoma brain metastases . Neurosurgery. 2007 Mar;60(3):471–81. 10.1227/01.Neu.0000255342.10780.52 doi: https://doi.org/10.1227/01.NEU.0000255342.10780.52
  130. Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study . Lancet Oncol. 2014 Apr;15(4):387–95. 10.1016/S1470-2045(14)70061-0
  131. Yamamoto M, Serizawa T, Sato Y, Higuchi Y, Kasuya H. Stereotactic Radiosurgery Results for Patients with 5-10 versus 11-20 Brain Metastases: A Retrospective Cohort Study Combining 2 Databases Totaling 2319 Patients . World Neurosurg. 2021 Feb;146:e479–91. 10.1016/j.wneu.2020.10.124
  132. Chen WC, Baal UH, Baal JD, Pai JS, Boreta L, Braunstein SE, et al. Efficacy and Safety of Stereotactic Radiosurgery for Brainstem Metastases: A Systematic Review and Meta-analysis . JAMA Oncol. 2021 Jul;7(7):1033–40. 10.1001/jamaoncol.2021.1262
  133. Redmond KJ, Gui C, Benedict S, Milano MT, Grimm J, Vargo JA, et al. Tumor Control Probability of Radiosurgery and Fractionated Stereotactic Radiosurgery for Brain Metastases . Int J Radiat Oncol Biol Phys. 2021 May;110(1):53–67. 10.1016/j.ijrobp.2020.10.034
  134. Kennedy WR, DeWees TA, Acharya S, Mahmood M, Knutson NC, Goddu SM, et al. Internal dose escalation associated with increased local control for melanoma brain metastases treated with stereotactic radiosurgery . J Neurosurg. 2020 Dec;135(3):855–61. 10.3171/2020.7.Jns192210 doi: https://doi.org/10.3171/2020.7.JNS192210
  135. Minniti G, D’Angelillo RM, Scaringi C, Trodella LE, Clarke E, Matteucci P, et al. Fractionated stereotactic radiosurgery for patients with brain metastases . J Neurooncol. 2014 Apr;117(2):295–301. 10.1007/s11060-014-1388-3
  136. Kayama T, Sato S, Sakurada K, Mizusawa J, Nishikawa R, Narita Y, et al.; Japan Clinical Oncology Group. Effects of Surgery With Salvage Stereotactic Radiosurgery Versus Surgery With Whole-Brain Radiation Therapy in Patients With One to Four Brain Metastases (JCOG0504): A Phase III, Noninferiority, Randomized Controlled Trial. J Clin Oncol. 2018 Jun;JCO2018786186(33):JCO2018786186. 10.1200/JCO.2018.78.6186; Epub ahead of print.
  137. Mahajan A, Ahmed S, McAleer MF, Weinberg JS, Li J, Brown P, et al. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017 Aug;18(8):1040–8. 10.1016/S1470-2045(17)30414-X
  138. Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013 Feb;31(5):616–22. 10.1200/JCO.2012.44.6112
  139. Chiarion-Sileni V, et al. Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). J Clin Oncol. 2015 Jun;33(18 _suppl):LBA1. 10.1200/jco.2015.33.18_suppl.lba1
  140. Ascierto PA, Dréno B, Larkin J, Ribas A, Liszkay G, Maio M, et al. 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. Clin Cancer Res. 2021 Oct;27(19):5225–35. 10.1158/1078-0432.CCR-21-0809
  141. Borius PY, Régis J, Carpentier A, Kalamarides M, Valery CA, Latorzeff I. Safety of radiosurgery concurrent with systemic therapy (chemotherapy, targeted therapy, and/or immunotherapy) in brain metastases: a systematic review. Cancer Metastasis Rev. 2021 Mar;40(1):341–54. 10.1007/s10555-020-09949-9
  142. Lehrer EJ, Gurewitz J, Bernstein K, Kondziolka D, Fakhoury KR, Rusthoven CG, et al. Concurrent Administration of Immune Checkpoint Inhibitors and Stereotactic Radiosurgery Is Well-Tolerated in Patients With Melanoma Brain Metastases: An International Multicenter Study of 203 Patients. Neurosurgery. 2022 Dec;91(6):872–82. 10.1227/neu.0000000000002127
  143. Lehrer EJ, Kowalchuk RO, Gurewitz J, Bernstein K, Kondziolka D, Niranjan A, et al. Concurrent Administration of Immune Checkpoint Inhibitors and Single Fraction Stereotactic Radiosurgery in Patients With Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma Brain Metastases. Int J Radiat Oncol Biol Phys. 2023 Jul;116(4):858–68. 10.1016/j.ijrobp.2023.01.017
  144. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990 Feb;322(8):494–500. 10.1056/NEJM199002223220802
  145. Carrubba CJ, Vitaz TW. Factors affecting the outcome after treatment for metastatic melanoma to the brain. Surg Neurol. 2009 Dec;72(6):707–11. 10.1016/j.surneu.2009.03.005
  146. Lonser RR, Song DK, Klapper J, Hagan M, Auh S, Kerr PB, et al. Surgical management of melanoma brain metastases in patients treated with immunotherapy. J Neurosurg. 2011 Jul;115(1):30–6. 10.3171/2011.3.JNS091107
  147. Miller D, Zappala V, El Hindy N, Livingstone E, Schadendorf D, Sure U, et al. Intracerebral metastases of malignant melanoma and their recurrences—a clinical analysis. Clin Neurol Neurosurg. 2013 Sep;115(9):1721–8. 10.1016/j.clineuro.2013.03.019
  148. Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol. 2004 Apr;22(7):1293–300. 10.1200/JCO.2004.08.140
  149. Schödel P, Schebesch KM, Brawanski A, Proescholdt MA. Surgical resection of brain metastases-impact on neurological outcome. Int J Mol Sci. 2013 Apr;14(5):8708–18. 10.3390/ijms14058708
  150. Paek SH, Audu PB, Sperling MR, Cho J, Andrews DW. Reevaluation of surgery for the treatment of brain metastases: review of 208 patients with single or multiple brain metastases treated at one institution with modern neurosurgical techniques. Neurosurgery. 2005 May;56(5):1021–34.
  151. Zacest AC, Besser M, Stevens G, Thompson JF, McCarthy WH, Culjak G. Surgical management of cerebral metastases from melanoma: outcome in 147 patients treated at a single institution over two decades. J Neurosurg. 2002 Mar;96(3):552–8. 10.3171/jns.2002.96.3.0552
  152. Cust AE, Badcock C, Smith J, Thomas NE, Haydu LE, Armstrong BK, et al. A risk prediction model for the development of subsequent primary melanoma in a population-based cohort. Br J Dermatol. 2020 May;182(5):1148–57. 10.1111/bjd.18524
  153. Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, et al. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017 Jul;18(7):863–73. 10.1016/S1470-2045(17)30429-1
  154. Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016 Jul;17(7):976–83. 10.1016/S1470-2045(16)30053-5
  155. Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018 May;19(5):672–81. 10.1016/S1470-2045(18)30139-6
  156. Tawbi HA, Forsyth PA, Hodi FS, Algazi AP, Hamid O, Lao CD, et al. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncol. 2021 Dec;22(12):1692–704. 10.1016/S1470-2045(21)00545-3
  157. Lehrer EJ, Peterson J, Brown PD, Sheehan JP, Quiñones-Hinojosa A, Zaorsky NG, et al. Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: an international meta-analysis of individual patient data. Radiother Oncol. 2019 Jan;130:104–12. 10.1016/j.radonc.2018.08.025
  158. Lu VM, Goyal A, Rovin RA, Lee A, McDonald KL. Concurrent versus non-concurrent immune checkpoint inhibition with stereotactic radiosurgery for metastatic brain disease: a systematic review and meta-analysis. J Neurooncol. 2019 Jan;141(1):1–12. 10.1007/s11060-018-03020-y
  159. Petrelli F, De Stefani A, Trevisan F, Parati C, Inno A, Merelli B, et al. Combination of radiotherapy and immunotherapy for brain metastases: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2019 Dec;144:102830. 10.1016/j.critrevonc.2019.102830
  160. Pin Y, Paix A, Todeschi J, Antoni D, Proust F, Noël G. Brain metastasis formation and irradiation by stereotactic radiation therapy combined with immunotherapy: A systematic review. Crit Rev Oncol Hematol. 2020 May;149:102923. 10.1016/j.critrevonc.2020.102923
  161. Bhatia A, Birger M, Veeraraghavan H, Um H, Tixier F, McKenney AS, et al. MRI radiomic features are associated with survival in melanoma brain metastases treated with immune checkpoint inhibitors. Neuro Oncol. 2019 Dec;21(12):1578–86. 10.1093/neuonc/noz141
  162. van Opijnen MP, Dirven L, Coremans IE, Taphoorn MJ, Kapiteijn EH. The impact of current treatment modalities on the outcomes of patients with melanoma brain metastases: A systematic review. Int J Cancer. 2020 Mar;146(6):1479–89. 10.1002/ijc.32696
  163. Moyers JT, Chong EG, Peng J, Tsai HH, Sufficool D, Shavlik D, et al. Real world outcomes of combination and timing of immunotherapy with radiotherapy for melanoma with brain metastases. Cancer Med. 2021 Feb;10(4):1201–11. 10.1002/cam4.3716
  164. Weaver BD, Goodman JR, Jensen R. Concurrent Radiosurgery and Systemic Therapies for Melanoma Brain Metastases: A Systematic Review. Cureus. 2019 Nov;11(11):e6147. 10.7759/cureus.6147
  165. Rauschenberg R, Bruns J, Brütting J, Daubner D, Lohaus F, Zimmer L, et al. Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases. Eur J Cancer. 2019 Mar;110:11–20. 10.1016/j.ejca.2018.12.023
  166. Tan XL, Le A, Scherrer E, Tang H, Kiehl N, Han J, et al. Systematic literature review and meta-analysis of clinical outcomes and prognostic factors for melanoma brain metastases. Front Oncol. 2022 Dec;12:1025664. 10.3389/fonc.2022.1025664
  167. Amaral T, Tampouri I, Eigentler T, Keim U, Klumpp B, Heinrich V, et al. Immunotherapy plus surgery/radiosurgery is associated with favorable survival in patients with melanoma brain metastasis. Immunotherapy. 2019 Mar;11(4):297–309. 10.2217/imt-2018-0149
  168. Gabani P, Fischer-Valuck BW, Johanns TM, Hernandez-Aya LF, Keller JW, Rich KM, et al. Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: patterns of care and treatment outcomes. Radiother Oncol. 2018 Aug;128(2):266–73. 10.1016/j.radonc.2018.06.017
  169. Kotecha R, Miller JA, Venur VA, Mohammadi AM, Chao ST, Suh JH, et al. Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome. J Neurosurg. 2018 Jul;129(1):50–9. 10.3171/2017.1.JNS162797
  170. Martins F, Schiappacasse L, Levivier M, Tuleasca C, Cuendet MA, Aedo-Lopez V, et al. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study. J Neurooncol. 2020 Jan;146(1):181–93. 10.1007/s11060-019-03363-0
  171. Sloot S, Chen YA, Zhao X, Weber JL, Benedict JJ, Mulé JJ, et al. Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies. Cancer. 2018 Jan;124(2):297–305. 10.1002/cncr.30946
  172. Ge Y, Che X, Gao X, Zhao S, Su J. Combination of radiotherapy and targeted therapy for melanoma brain metastases: a systematic review. Melanoma Res. 2021 Oct;31(5):413–20. 10.1097/CMR.0000000000000761
  173. Liao G, Fu Y, Arooj S, Khan M, Li X, Yan M, et al. Impact of Previous Local Treatment for Brain Metastases on Response to Molecular Targeted Therapy in BRAF-Mutant Melanoma Brain Metastasis: A Systematic Review and Meta-Analysis. Front Oncol. 2022 Jun;12:704890. 10.3389/fonc.2022.704890
  174. Hassel JC, Schank TE, Smetak H, Mühlbauer J, Salzmann M, Machiraju D, et al. Evaluation of radio-immunotherapy sequence on immunological responses and clinical outcomes in patients with melanoma brain metastases (ELEKTRA). OncoImmunology. 2022 Apr;11(1):2066609. 10.1080/2162402X.2022.2066609
  175. Glitza Oliva IC, Ferguson SD, Bassett R Jr, Foster AP, John I, Hennegan TD, et al. Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nat Med. 2023 Apr;29(4):898–905. 10.1038/s41591-022-02170-x
  176. K. B. Rami A. El Shafie, Karina Böhm, Dorothea Weber, Kristin Lang, Fabian Schlaich, Sebastian Adeberg,Angela Paul, Matthias F. Haefner, Sonja Katayama, Juliane Hörner-Rieber,Philipp Hoegen, Sarah Löw, Jürgen Debus,Jürgen Debus, Stefan Rieken, Denise Bernhardt, Palliative Radiotherapy for Leptomeningeal Carcinomatosis–Analysis of Outcome, Prognostic Factors, and Symptom Response, Front. Oncol, vol. Volume 8 - 2018 08 January 2019.
  177. Yang JT, Wijetunga NA, Pentsova E, Wolden S, Young RJ, Correa D, et al. Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis. J Clin Oncol. 2022 Nov;40(33):3858–67. 10.1200/JCO.22.01148
  178. Dummer R, Brase JC, Garrett J, Campbell CD, Gasal E, Squires M, et al. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. Lancet Oncol. 2020 Mar;21(3):358–72. 10.1016/S1470-2045(20)30062-0
  179. Larkin J, Del Vecchio M, Mandalá M, Gogas H, Arance Fernandez AM, Dalle S, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238. Clin Cancer Res. 2023 Sep;29(17):3352–61. 10.1158/1078-0432.CCR-22-3145
  180. Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, et al.; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC). European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. Eur J Cancer. 2022 Jul;170:236–55. 10.1016/j.ejca.2022.03.008
  181. Ackermann DM, Dieng M, Medcalf E, Jenkins MC, van Kemenade CH, Janda M, et al. Assessing the Potential for Patient-led Surveillance After Treatment of Localized Melanoma (MEL-SELF): A Pilot Randomized Clinical Trial. JAMA Dermatol. 2022 Jan;158(1):33–42. 10.1001/jamadermatol.2021.4704
  182. Gassenmaier M, Stec T, Keim U, Leiter U, Eigentler TK, Metzler G, et al. Incidence and characteristics of thick second primary melanomas: a study of the German Central Malignant Melanoma Registry. J Eur Acad Dermatol Venereol. 2019 Jan;33(1):63–70. 10.1111/jdv.15194
  183. Zissimopoulos A, Karpouzis A, Karaitianos I, Baziotis N, Tselios I, Koutis C. [Serum levels of S-100b protein after four years follow-up of patients with melanoma]. Hell J Nucl Med. 2006;9(3):204–7.
  184. Dicker TJ, Kavanagh GM, Herd RM, Ahmad T, McLaren KM, Chetty U; Scottish Melanoma Group. A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Br J Dermatol. 1999 Feb;140(2):249–54. 10.1046/j.1365-2133.1999.02657.x
  185. Trotter SC, Sroa N, Winkelmann RR, Olencki T, Bechtel M. A Global Review of Melanoma Follow-up Guidelines. J Clin Aesthet Dermatol. 2013 Sep;6(9):18–26.
  186. Xing Y, Bronstein Y, Ross MI, Askew RL, Lee JE, Gershenwald JE, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst. 2011 Jan;103(2):129–42. 10.1093/jnci/djq455
  187. S3-Leitlinie zur Diagnostik, Therapie und Nachsorge des Melanoms in German Melanoma AWMF-S3-Guideline 2020: https://register.awmf.org/assets/guidelines/032-024OLl_S3_Melanom-Diagnostik-Therapie-Nachsorge_2020-08.pdf
  188. Riquelme-Mc Loughlin C, Podlipnik S, Bosch-Amate X, Riera-Monroig J, Barreiro A, Espinosa N, et al. Diagnostic accuracy of imaging studies for initial staging of T2b to T4b melanoma patients: A cross-sectional study. J Am Acad Dermatol. 2019 Dec;81(6):1330–8. 10.1016/j.jaad.2019.05.076
  189. Deichmann M, Benner A, Bock M, Jäckel A, Uhl K, Waldmann V, et al. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol. 1999 Jun;17(6):1891–6. 10.1200/JCO.1999.17.6.1891
  190. Beyeler M, Waldispuhl S, Strobel K, Joller-Jemelka HI, Burg G, Dummer R. Detection of melanoma relapse: first comparative analysis on imaging techniques versus S100 protein. Dermatology. 2006;213(3):187–91. 10.1159/000095034
  191. Egberts F, Kotthoff EM, Gerdes S, Egberts JH, Weichenthal M, Hauschild A. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma . Eur J Cancer. 2012 Mar;48(5):695–702. 10.1016/j.ejca.2011.08.007
  192. Gebhardt C, Lichtenberger R, Utikal J. Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patients. J Dtsch Dermatol Ges. 2016 Feb;14(2):158–64. 10.1111/ddg.12727
  193. Pikturniene R, Cesas A, Jarmalaite S, Razbadauskas A, Urbonas V. Harnessing ctDNA in Advanced Melanoma: A Promising Tool for Informed Clinical Decisions. Cancers (Basel). 2024 Mar;16(6):1197. 10.3390/cancers16061197
  194. Long GV, Ascierto PA, Guo J, Chandra S, Tarhini AA, Muñoz E, et al. Nivolumab plus relatlimab vs nivolumab alone for the adjuvant treatment of completely resected stage III–IV melanoma: primary results from RELATIVITY-098 [Meeting Abstract: 2025 ASCO Annual Meeting II]. J Clin Oncol. 2025;43(17 suppl.): 10.1200/JCO.2025.43.17_suppl.LBA9500